Hussein Abid

Mr. Hussein Abid

Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Csongrád, Hungary
orcid
Clinical Laboratory Scientist

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
NJNabaa A. Jasim
Nabaa A. Jasim
FAFadhl A. Al-Gasha'A
Fadhl A. Al-Gasha'A
MAMohammed F. Al-Marjani
Mohammed F. Al-Marjani
AAAwas H. Al-Rahal
Awas H. Al-Rahal
Hussein AbidHussein Abid
Hussein Abid
ARAhmed M. Rheima
Ahmed M. Rheima

1 April 2021 in Baghdad Journal of Biochemistry and Applied Biological Sciences
Verified
Journal Article
Open access
PDF file
Hussein AbidHussein Abid
Hussein Abid
ZAZainab Abid
Zainab Abid
SAShireen Abid
Shireen Abid
Cardiovascular diseases (CVD) represent a major cause of mortality and morbidity worldwide. To date, many physicians still requesting traditional lipid profile tests (TG, TC, HDL-C, and LDL-C) to confirm the clinical diagnosis related to CVD. However, using these tests may be inadequate for the prediction of CVD risk, especially in intermediate risk. For better clinical practice, laboratory diagnostic alternatives should constantly be evaluated and developed by physicians and laboratory scientists. In this review, we sought to focus on the benefits of lipid ratios (CRI-, CRI-II, AIP, AC, and CHOLindex) in supporting clinical diagnosis and how they can be calculated. To attain this aim, a literature search in reputed databases (PubMed and Scopus) was performed and peer-reviewed research articles were included to conduct this review. Short theoretical and practical notes about each index were accordingly included along with calculation formulas. Thus, the current article can assist new researchers and young physicians to review what supports their knowledge in managing early CVDs.

1 July 2021 in Baghdad Journal of Biochemistry and Applied Biological Sciences
Verified
Journal Article
Open access
PDF file
SAShukrya Alwan
Shukrya Alwan
MAMuna Al-Saeed
Muna Al-Saeed
Hussein AbidHussein Abid
Hussein Abid
Background: Biosynthesized silver nanoparticles (AgNPs) are widely used in various biomedical applications. However, limited reports are currently available about the safety of biofabricated AgNPs using Cinnamomum zeylanicum bark extracts. Objectives: The current study is aimed to assess the potential toxicity of biosynthesized AgNPs (using C. zeylanicum) by subacute oral administration in experimental rats. Methods: AgNPs were biofabricated using methanol extract of C. zeylanicum bark and characterized by scanning electron microscopy (SEM) and atomic force microscopy (AFM). Twenty-four Rattus norvegicus female rats were divided into 4 groups (6 animals per group) as follows: Group-I was the control, while groups II, III, and IV were given 0.85, 1.76 and 3.53 mg/kg doses of AgNPs, respectively for 14 consecutive days. After 14 days of oral administration of AgNPs, serum levels of malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) were measured using an ELISA technique. Serum concentrations of urea, creatinine, aspartate transaminase (AST) and alanine transaminase (ALT) were also determined as well as histopathologic features of the liver and the kidney. Results: AgNPs did not induce any changes in mean body weight, biochemical parameters (AST, ALT, urea and creatinine), oxidative stress biomarkers (MDA, SOD and CAT) and histopathologic features (of the liver and kidneys) of the treated groups when compared to control group. Conclusions: Our findings suggest that the oral administration of biogenic AgNPs (biofabricated using methanol extract of C. zeylanicum) to rats at a specific dose is relatively safe and does not show any signs of toxicity.

1 January 2022 in Baghdad Journal of Biochemistry and Applied Biological Sciences
Verified
Journal Article
Open access
PDF file
SAShireen Al-Tameemi
Shireen Al-Tameemi
NHNajwa Hameed
Najwa Hameed
KGKarina Gomes
Karina Gomes
Hussein AbidHussein Abid
Hussein Abid
Background and objective: Cigarette smoking is a leading cause of a wide range of critical health problems such as cancers, especially those related to the respiratory system. Although studies are continuing on the smoking-related inflammatory responses, limited reports are there to explore how such responses can be affected by the smoking intensity. Therefore, the current communication aimed to shed light on how smoking and smoking intensity can affect some inflammatory and anti-inflammatory biomarkers. Methods: A total of 159 subjects (108 smokers and 51 non-smokers) were enrolled in this cross-sectional study. Their sociodemographic, smoking intensity and blood samples were obtained and processed using approved methodologies. The blood plasma samples were used to quantify interleukin 6 (IL-6), IL-10, tumor necrosis factor-alpha (TNF-α), C-reactive protein, D-dimer, and ferritin by using ELISA. The gained data was then analyzed using GraphPad Prism software to assess the variations. Results: Both IL-6 and TNF-α are elevated markedly (p<0.001) in smoker subjects when compared with non-smoker ones (IL-6: 2.58±0.98 vs. 1.858±0.6256 pg/ml, TNF-α: 28.38±7.162 vs. 22.64±7.257 pg/ml). However, no significant differences were observed in other biomarkers comparing the groups, as well as no significant association was evidenced based on smoking intensity among smokers. Conclusions: The findings might point to a relationship between smoking and the elevation of IL-6 and TNF-α levels in a cigarette dose-dependent manner.

2 January 2020 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
JSJehan Abdul-Sattar Salman
Jehan Abdul-Sattar Salman
NMNibras Nazar Mahmood
Nibras Nazar Mahmood
BABan Oday Abdulsattar
Ban Oday Abdulsattar
Hussein AbidHussein Abid
Hussein Abid
Viral infections have gained great attention following the rapid emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic around the globe. Even with the continuous research on developing vaccines and antiviral agents against various viral infections, no specific treatment or vaccine has been approved for many enteric or respiratory viral infections; in addition, the efficiency of currently available treatments is still limited. One of the most reliable and recommended strategies to control viral infections is prevention. Recently, intense studies are focusing on a promising approach for treating/preventing various viral infections using probiotics. As per the World Health Organization (WHO), probiotics can be defined as “live microorganisms which, when administered in adequate amount, confer a health benefit to the host.” The use of probiotics is a simple, cost-effective, and safe strategy to prevent viral infections, specifically; respiratory tract and intestinal ones, by different means such as stimulating the host’s immune response or modulating gut microbiota. In this rapid review, we emphasize the protective effects of probiotics against viral infections and proposed mechanisms for protection that might offer a novel and cost-effective treatment against current and newly discovered viruses like SARS-CoV-2.

1 October 2022 in Baghdad Journal of Biochemistry and Applied Biological Sciences
Verified
Journal Article
Open access
PDF file
NANisreen Abid
Nisreen Abid
EHEntisar Hamad
Entisar Hamad
MIMusaab Ibrahim
Musaab Ibrahim
Hussein AbidHussein Abid
Hussein Abid
Background and objective: The medicinal effects of flavonoids are widely described in the literature; however, their antimicrobial effects against antibiotic resistant bacteria are yet to be highlighted. This study was aimed at investigating the growth and biofilm inhibitory effects of taxifolin, a flavonoid, against vancomycin-resistant Staphylococcus aureus (VRSA). Methods: Seven VRSA isolates were used to assess the antimicrobial and antibiofilm influence of taxifolin. The agar-well diffusion method was used to determine the zones of inhibition caused by taxifolin, and resazurin-based microdilution technique was used to assess the minimum inhibitory concentration. Crystal violet staining technique was used to assess the biomass of biofilms formed by the microorganisms. GraphPad Prism software was used to present the data in figures. Results: Taxifolin inhibited bacterial growth in a dose-dependent fashion and reduced bacterial viability. It similarly attenuated the biofilm production activity of bacterial isolates in a dose-dependent manner. Conclusions: Current findings suggest the antibacterial and antibiofilm influence of taxifolin against VRSA in a dose-dependent manner.